Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Enginzyme AB has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and 1 distinct art unit. CRUM, MARY ABOU NADER is the busiest examiner, currently managing 1 pending office action. With only 1 pending office action, the company's current prosecution activity is highly centralized.
The involvement of 1 distinct examiner and 1 distinct art unit means that the company's immediate success in the Biotechnology & Pharmaceuticals area is tied to a single point of review. Practitioners can dedicate their attention to the specific procedural history and preferences of CRUM, MARY ABOU NADER, as there are no other active matters or examiners to consider in the current data set. This 1 pending office action allows for a concentrated effort within 1 distinct art unit, ensuring that the prosecution strategy is tailored specifically to the examiner's requirements and the unit's standards.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +29.6% |
| CRUM, MARY ABOU NADER | 1 | 40.4% | +65.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724381 | C-NUCLEOSIDE MONOPHOSPHATE SYNTHESIS | CRUM, MARY ABOU NADER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18869649 | BATCH PROCESS FOR ENZYMATIC MODIFICATION OF LIPIDS | STEADMAN, DAVID J | — |
| 18724381 | C-NUCLEOSIDE MONOPHOSPHATE SYNTHESIS | CRUM, MARY ABOU NADER | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18869649 | BATCH PROCESS FOR ENZYMATIC MODIFICATION OF LIPIDS | STEADMAN, DAVID J | — | §103§112DP | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18724381 | C-NUCLEOSIDE MONOPHOSPHATE SYNTHESIS | CRUM, MARY ABOU NADER | 1657 | §103§112 | Non-Final OA | — | Pending | Jun 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial